Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NRG-GU008 trial: what clinicians have said so far
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT04134260 ↗
- Active, not recruiting
- NRG Oncology
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on NRG-GU008 (apalutamide in node-positive prostate cancer after radical prostatectomy) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NRG-GU008 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 7 posts on X | |
| 4 YouTube videos |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Prostate Adenocarcinoma; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
- Interventions
- Apalutamide; Biospecimen Collection; Bone Scan; Computed Tomography; Hormone Therapy; Magnetic Resonance Imaging; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy
- Arms
- Arm I (hormone therapy, radiation therapy) · Active comparator
- Arm II (hormone therapy, radiation therapy, apalutamide) · Experimental
- Enrollment
- 586 (estimated)
- Primary outcomes
- Metastasis-free survival (MFS)
- Sponsor
- NRG Oncology with National Cancer Institute (NCI)
- Start
- Apr 16, 2020
- Primary completion
- Nov 1, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04134260 · updated Aug 17, 2026
Publications
linked from the registry- Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr;211(4):518-525. doi: 10.1097/JU.0000000000003891. Epub 2024 Feb 29. PubMed 38421243